Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Opens in a new tab or window While high-dose chemotherapy and autologous hematopoietic cell transplantation (HCT) can deepen ...

Researchers sought to better understand the experiences of patients living with multiple myeloma and their perceptions of palliative care.

A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...

Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...